¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Weigert's fibrin stain"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® Gram stain ÇÑ±Û ±×¶÷¿°»ö
¼³¸í   
  ¹Ì»ý¹°À» ¿°»öÇϴ ¹æ¹ý ÁßÀÇ Çϳª. 1884³â µ§¸¶Å©ÀÇ ÀÇ»ç H.C.J. ±×¶÷(1853~ 1938)ÀÌ °í¾ÈÇѠƯ¼ö ¿°»ö¹ýÀÌ´Ù. ÀÌ ¿°»ö¹ýÀ» »ç¿ëÇϸ頹̻ý¹°Àº ¾ç¼º±Õ°ú À½¼º±ÕÀÇ 2¹«¸®·Î Å©°Ô ³ª´¶´Ù. ¿°»ö¹ýÀº ±ÕÀ» À¯¸®¸é¿¡ ¹Ù¸£°í °¡¿­ °íÁ¤ÇÑ´Ù. Á¨½Ã¾È¹ÙÀÌ¿À·¿, Å©¸®½ºÅ» ¹ÙÀÌ¿À·¿, ¸ÞÆ¿¹ÙÀÌ¿À·¿ µî ÆÄ¶ó·ÎÁƴҸ°°è »ö¼ÒÀÇ ¾î´À Çϳª¸¦ »ç¿ëÇÏ¿© ¿ì¼± ¿°»öÇϰí À̾ ·ç°ñ¾×À» ÀÛ¿ë½ÃŲ µÚ, ¿¡Åº¿Ã ¶Ç´Â ¾Æ¼¼ÅæÀ¸·Î Å»»öÇÑ´Ù. À̶§ Å»»öµÇÁö ¾Ê°í º¸¶ó»öÀ» Å¸³ª³»´Â °ÍÀ» ±×¶÷¾ç¼º±ÕÀ̶ó ºÎ¸£¸ç, Æ÷µµ¾Ë±Õ-Æó·Å¾Ë±Õ-»ç½½¾Ë±Õ µîÀÌ ´ëÇ¥ÀûÀΠ¿¹ÀÌ´Ù. Å»»öµÇ¸é ±×¶÷À½¼º±ÕÀ̶ó ºÎ¸£¸ç, ´ëÀå±Õ-³ì³ó±Õ µîÀÌ ÀÖ´Ù. ÃÖÈÄ¿¡ »çÇÁ¶ó´Ñ, Ç«½Å µî Àû»ö°èÀÇ »ö¼Ò¾×À¸·Î ÈÄ¿°»öÀ» ÇÑ´Ù. ¹Ì»ý¹°ÀÇ °¨º°¿¡ Áß¿äÇÑ ¿°»ö¹ýÀ̸砿°»ö¼ºÀÇ Â÷À̴ ¿µ¾ç¿ä±¸¼º, È­Çпä¹ýÁ¦(Ç×»ý¹°Áú µî)¿¡ ´ëÇÑ °¨¼ö¼ºÀÇ Â÷À̿͵µ °ü·ÃµÇ´Â Á¡ÀÌ ¸¹À¸¹Ç·Î »ç¿ë¾àÁ¦ÀÇ ¼±Åýÿ¡µµ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. ±×¶÷¾ç¼º±Õ°ú À½¼º±ÕÀÇ Â÷À̴ ¼¼±Õº®ÀÇ ±¸Á¶¿¡ Àִµ¥, ¾ç¼º±ÕÀº ¼¼Æ÷¸·ÀÇ ¹Ù±ùÂÊ ÆéƼµå±Û¸®Ä­À̶ó´Â ´ç´Ü¹éÁúÃþÀÇ µÎ²²°¡ 20~80nm³ª µÇ°í, ±×·¥À½¼º±ÕÀÇ ÆéƼµå±Û¸®Ä­ ÃþÀº 2~3nm·Î ¾ã°í, ´Ù½Ã ¹Ù±ùÂÊ¿¡ ¿Ü¸·À̶ó ºÎ¸£´Â ÃþÀÌ ÀÖ´Ù.
¿µ¹® fibrin ÇÑ±Û ¼¶À¯¼Ò
¼³¸í   
  Çǰ¡ ±»À» ¶§ ¼¶À¯¼Ò¿¡ Æ®·ÒºóÀÌ ÀÛ¿ëÇÏ¿© »ý±â´Â ¼¶À¯ °°Àº ´Ü¹éÁú. ¹«»öÀ̳ª ¿¯Àº È²»öÀ» ¶í °íü·Î, ¹°¿¡ Àß ³ìÁö ¾ÊÀ¸¸ç Ç÷±¸¿Í ¾ûŰ¾î ÇǸ¦ ±»°Ô ÇÏ¿© ÃâÇ÷À» ±×Ä¡°Ô ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Weigert stain
    1. ¹ÙÀ̰Ը£Æ®¿°»ö 2. ¹ÙÀ̰Ը£Æ®¿°·á
  • fibrin
    ¼¶À¯¼Ò, ÇǺ기
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°, ÇǺ기ºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü, ÇǺ기Ç÷Àü
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
  • acid-fast stain
    Ç׻꿰»ö
  • basic stain
    ¿°±â¿°»ö
  • biological stain
    »ý¹°ÇÐÀû¿°»ö
  • contrast stain
    ´ëÁ¶¿°»ö
  • counter stain
    ´ëÁ¶¿°»ö
  • differential stain
    °¨º°¿°»ö
  • double stain
    ÀÌÁß¿°»ö
  • electron stain
    ÀüÀÚ¿°»ö
  • Gomori methenamine-silver stain
    °í¸ð¸®¸ÞÅ׳ª¹ÎÀº¿°»ö
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • stain
    ¿°»ö, ¿°·á, Âø»ö
  • acid-fast stain
    Ç׻꿰»ö
  • Gram stain
    ±×¶÷¿°»ö
  • silver stain
    Àº¿°»ö
  • Ziehl-Neelsen stain
    Ä¥³Ú¼¾¿°»ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • fibrin thrombus
    ¼¶À¯¼ÒÇ÷Àü
  • fibrin degradation product
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • myogen fibrin
    ¹Ì¿À°Õ¼¶À¯¼Ò
  • acid-fast stain
    Ç׻꿰»ö
  • basic stain
    ¿°±â¿°»ö
  • biological stain
    »ý¹°ÇÐÀû¿°»ö
  • contrast stain
    ´ëÁ¶¿°»ö
  • counter stain
    (¢¡counterstain) ´ëÁ¶¿°»ö
  • differential stain
    ºÐº°¿°»ö
  • electron stain
    ÀüÀÚ¿°»ö
  • fluorescent antibody stain
    Çü±¤Ç×ü¿°»ö
  • Gram stain
    ±×¶÷¿°»ö
  • heavy-metal stain
    Á߱ݼӿ°»ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • Fibrin-stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­)
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
  • gluten fibrin
    ±Û·çÅÙ¼¶À¯¼Ò.
  • Alician blue stain
    ¾Ë¸®¼¢ ºí·ç ¿°»ö
  • Congo red stain
    Äá°í·¹µå ¿°»ö(æøßä)
  • Hansel secretion stain
    ÇѼ¿ºÐºñ¹°¿°»ö
  • Heidenhain s iron hematoxylin stain
    ÇÏÀ̵§ÇÏÀΠö Ç츶Åå½Ç¸° ¿°»ö¹ý.
  • India ink stain
    Àεð¾ð À×Å© ¿°»ö
  • Kinyoun stain
    Ű³â¿°»ö
  • Nissls stain
    ´Ï½½¿°»ö.
  • PAS stain
    PAS ¿°»ö
  • PAS stain[ing]
    PAS¿°»ö(¹ý)
  • Papanicolaou stain
    ÆÄÆÄ´ÏÄݷο°»ö
  • Romanowsky stain
    ·Î¸¶³ëÇÁ½ºÅ°¿°»ö
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carmine fibrin
    Ä«¸£¹Î¼¶À¯¼Ò(¡­àéë«áÈ).
  • crystal fibrin
    °áÁ¤¼¶À¯¼Ò, ¼öÁ¤Ã¼¼¶À¯¼Ò(¡­àéë«áÈ).
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ), È­À̺기.
  • fibrin abnormality
    ¼¶À¯¼ÒÀÌ»ó
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«, ¼¶À¯¼ÒÀÀ°í
  • fibrin clot
    ¼¶À¯¼ÒÀÀ±«(¡­ëêÎÔ).
  • fibrin degradation product
  • fibrin degradation products =fDP
    ¼¶À¯¼ÒºÐÇØ»ê¹°
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibrin stabilizing factor =FSF
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ(¡­äÌïÒì×í­), ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤ÀÎÀÚ, ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ.
  • glomerulosclerosis,fibrin cap
    ¼¶À¯¼Òµ¤°³
  • gluten fibrin
    ±Û·çÅÙ¼¶À¯¼Ò.
  • myogen fibrin
    ¹Ì¿À°ÕÈ­À̺기.
  • acid fast stain
    Ç×»ê(¼º) ¿°»ö(¡­æøßä).
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Diff-Quik stain
    µðÅ¥¿°»ö
  • Giemsa stain
    ±èÀÚ¿°»ö
  • iodine stain
    ¿ä¿Àµå¿°»ö
  • iron-hematoxylin stain
    öÇ츶Åå½Ç¸°¿°»ö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lipophilic stain
    Ä£ÁöÁú¼º(öÑò·òõàõ) ¿°»ö(æøßä)
  • vital stain
    »ý¿°»ö(ßææøßä)
  • fibrin
    ¼¶À¯¼Ò(àéë«áÈ)
  • fibrin monomer
    ¼¶À¯¼Ò ´Ü·®Ã¼(àéë«áÈÓ¤Õáô÷)
  • fibrin polymer
    ¼¶À¯¼Ò ÁßÇÕü(àéë«áÈñìùêô÷)
  • fibrin-stabilizing factor
    ¼¶À¯¼Ò ¾ÈÁ¤È­ÀÎÀÚ(àéë«áÈäÌïÒûùì×í­)
  • insoluble fibrin
    ºÒ¿ë¼º(ÝÕéÁàõ) È­À̺기
  • soluble fibrin
    "°¡¿ë(ʦéÁ)ÇǺ기, °¡¿ë ¼¶À¯¼Ò(ʦéÁàéë«áÈ)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • gram's stain
    ±×¶÷ ¿°»ö
  • tumor stain
    Á¾¾ç¿°»ö, Á¾¾çÁ¶¿µ
  • fibrin
    ¼¶À¯¼Ò, È­À̺기
  • fibrin plug
    È­À̺기ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin sealant
    ¼¶À¯¼Ò¹ÐÆóÁ¦(¹ÐºÀÁ¦)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AFB Stain Acid Fast Bacilli Stain
HE stain Hematoxylin-Eosin stain
SFC soluble fibrin complex; soluble fibrin-fibrinogen complex; spinal fluid count
WS Waardenburg syndrome; ward secretary; Warkany syndrome; Warthin-Starry [stain]; water soluble; water...
FSF Fibrin Stabilizing Factor(Factor XIII)
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PWS Port Wine Stain
FDP Fibrin Degradation Product
FbDP Fibrin Degradation Products
FS Fibrin Sealant
FG Fibrin glue
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • crystal fibrin
    °áÁ¤ ¼¶À¯¼Ò, ¼öÁ¤Ã¼ ¼¶À¯¼Ò
  • fibrin bodies of pleura
    È丷 ¼¶À¯ ¼Òü
    È丷°­ ±âÀúºÎ±Ù¿¡ ÀÖ´Â °¡µ¿¼º ¶Ç´Â Á¡Âø¼º, ±¸»ó, µ¿Áú¼º, ±×¸®°í ÇѰ谡 ¸íÈ®ÇÑ À¯¹éü·Î¼­, È丷 »ïÃâ¾×, ±âÈä ¶Ç´Â Ç÷±âÈäÁõ¿¡¼­ ÀÌÂ÷ÀûÀ¸·Î ¹ß»ýÇÑ´Ù.
  • fibrin plug
    È­À̺기 ÀüÀÚ, ¼¶À¯¼ÒÀü
  • fibrin thrombus
    È­À̺êÁø Ç÷Àü
  • acridine orange stain
    ¾ÆÅ©¸®µò ¿À·»Áö ¿°»ö
  • auramine-rhodamine stain
    ¿À¶ó¹Î-·Î´Ù¹Î ¿°»ö
  • Balch's stain
    ¹ßÃ÷ ¿°»ö¾×
    Ç÷¾×µµ¸» Ç¥º»À» ¿°»öÇϴµ¥ »ç¿ëÇÏ´Â Æú¸®Å©·Ò¸ÞÆ¿·»Ã».
  • dopa stain
    µµÆÄ ¿°»ö
  • fluorescent antibody stain
    Çü±¤ Ç×ü ¿°»ö
  • Macchiavello's stain
    ¸¶Å°¾Æº§·Î ¿°»ö
  • Mandelbaum's stain
    ¸¸µ¨¹Ù¿ò ¿°»ö¹ý
    ¸Åµ¶ ±ÕÀÇ »ýü ¿°»ö¹ý.
  • quesnel's stain
    Äù½º³Ú ¿°»ö¾×
    ¿ø½ÂÀ» ¿°»öÇϴµ¥ ¾²ÀÌ´Â ¾×À¸·Î, ¼ö´Ü¥²ÀÇ 80% ¾ËÄÚ¿Ã Æ÷È­¾× 20cc¿Í ¾à¿ë ¸ÞÆ¿·» ûÆ÷È­ ¿©¾× 300cc·Î ÀÌ·ç¾îÁø´Ù.
  • silver stain
    Àº ¿°»ö
  • simple stain
    ´Ü¼ø ¿°»ö
  • Smith-Pitfield stain
    ½º¹Ìµå-ÇÇÆ®ÇÇÀÏµå ¿°»ö¹ý
    Æí¸ðÀÇ ¿°»ö¹ýÀ¸·Î¼­, ¸Å¿° Àç·á´Â ¾Ï¸ð´Ï¾Æ ¸í¹ÝÀÇ Æ÷È­¾×°ú ½ÂÈ« Æ÷È­¾×À» È¥ÇÕÇÑ °Í¿¡ µî·®ÀÇ 10% ź´Ñ»ê¾×°ú ¹Ý·®ÀÇ 5% Ä«¸£º¼ÇªÅ©½Å ¾×À» ³Ö¾î¼­ ¸¸µé°í, À̰ÍÀ¸·Î ¸Å¿°ÇÑ ÈÄ Á¨Æ¼¾Æ´ÏÀÚ Æ÷È­ ¾ËÄÚ¿Ã ¿ë¾× 1¿ë°ú ¾Ï¸ð´Ï¾Æ ¸í¹Ý Æ÷È­¾× 10¿ëÀÇ ¿°»ö¾×À¸·Î ó¸®ÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
Weigert-Gram stain <technique> A stain for bacteria in tissues in which sections are stained in alum-haematoxylin, then in eosin, aniline methyl violet, and Lugol's solution.
(05 Mar 2000)
Weigert's iron haematoxylin stain <technique> A nuclear staining solution containing haematoxylin, ferric chloride, and hydrochloric acid; useful in combination with von Gieson's stain, especially for demonstrating connective tissue elements or Entamoeba histolytica in sections.
(05 Mar 2000)
Weigert's stain <technique> 1. For actinomyces, a staining method using immersion in a dark red orsellin solution in alcohol, then staining in crystal-violet solution.
See: iron haematoxylin.
2. For elastin, a staining solution of fuchsin, resorcin, and ferric chloride; elastic fibres stain blue-black.
3. For fibrin, a staining method using solutions of aniline-crystal violet and iodine-potassium iodide, then decolorizing in aniline oil and xylol; the fibrin is stained dark blue.
4. For myelin, a staining method using ferric chloride and haematoxylin; myelin stains deep blue, degenerated portions a light yellowish colour.
5. For neuroglia, a complicated process in which the final treatment is like that for staining fibrin; neuroglia and nuclei stain blue.
6. For reticulum, a silver impregnation technique in which reticulum appears as black, well-defined fibres without beading and with a relatively clear background.
(05 Mar 2000)
Weigert, Carl <person> German pathologist, 1845-1904.
See: Weigert's law, Weigert's iodine solution. See entries under stain.
(05 Mar 2000)
weigert-meyer rule <radiology> Applies to duplex collecting systems, upper-pole ureter, obstruction most likely to be hydronephrosis, inserts more inferiorly and medially in bladder, may insert into urethra, vagina, etc., males not incontinent: insertion above ext. Sphincter, associated with ureterocele, lower-pole ureter, reflux most likely to be pyelonephritis see also: drooping lily sign
(12 Dec 1998)
Weigert's iodine solution An iodine-potassium iodide mixture used as a reagent to alter crystal and methyl violet so that they are retained by certain bacteria and fungi.
(05 Mar 2000)
Weigert's law The loss or destruction of a part or element in the organic world is likely to result in compensatory replacement and overproduction of tissue during the process of regeneration or repair (or both), as in the formation of callus when a fractured bone heals.
Synonym: overproduction theory.
(05 Mar 2000)
human fibrin foam A dry artificial sponge of human fibrin prepared by clotting with thrombin a foam of a solution of human fibrinogen; the clotted foam is dried from the frozen state and heated; used as a topical anticoagulant.
(05 Mar 2000)
fibrin <protein> The insoluble protein formed from fibrinogen by the proteolytic action of thrombin during normal clotting of blood. Fibrin forms the essential portion of the blood clot.
(12 Nov 1997)
fibrin calculus A urinary calculus formed largely from fibrinogen in blood.
(05 Mar 2000)
fibrin degradation products <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot.
Normal value is less than 10 mcg/ml (micrograms per millilitre).
They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia.
Acronym: FDP
(23 Sep 2002)
fibrin destabilase <enzyme> Hydrolyses the epsilon-(gamma-glutamyl)-lysine bonds of stabilised fibrin
Pharmacological action: fibrinolytic agents
Registry number: EC 3.4.99.-
Synonym: destabilase
(26 Jun 1999)
fibrin fibrinogen degradation products <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis.
Pharmacological action: antithrombins.
(12 Dec 1998)
fibrin foam <chemical> A dry artificial sterile sponge of fibrin prepared by clotting with thrombin a foam or solution of fibrinogen. It is used in conjunction with thrombin as a haemostatic in surgery at sites where bleeding cannot be controlled by more common methods.
Pharmacological action: haemostatics, tissue adhesives.
(12 Dec 1998)
fibrinogen-fibrin conversion syndrome <syndrome> A syndrome characterised by hypofibrinogenaemia with incoagulable blood; it may be seen in abruptio placentae, prolonged retention of a dead foetus in an Rh-isosensitised mother, haemolytic blood reactions, bilateral renal cortical necrosis, and cases of trauma.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fibrin
    ¼¶À¯¼Ò
  • stain
    À» ´õ·´È÷´Ù
  • stain
    ¾ó·èÀ» ¹¯È÷´Ù;´õ·´È÷´Ù;(¸í¿¹¸¦)¼Õ»ó½ÃŰ´Ù;(À¯¸® µûÀ§¿¡)Âø»öÇÏ´Ù;´õ·¯¿öÁö´Ù;¾ó·èÁö´Ù;¾ó·è;Èì;¿ÀÁ¡;Âø»ö(Á¦)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á